New preclinical data on the antifibrotic effects of tasquinimod in myelofibrosis to be presented at EHA 2023

Lund, May 11 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that new data on the mechanisms by which tasquinimod ameliorates bone marrow fibrosis in a murine model of myelofibrosis will be presented in an oral session at the European Hematology Association Congress in Frankfurt, 8-11 June, 2023. Previous studies…